Business Description
Regeneron Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US75886F1075
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 4.01 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | 0.58 | |||||
Interest Coverage | 57.99 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 10.91 | |||||
Beneish M-Score | -2.51 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16 | |||||
3-Year EBITDA Growth Rate | 5 | |||||
3-Year EPS without NRI Growth Rate | 7.9 | |||||
3-Year FCF Growth Rate | 22.8 | |||||
3-Year Book Growth Rate | 32.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | 7.36 | |||||
Future 3-5Y Total Revenue Growth Rate | 9.5 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 25.92 | |||||
9-Day RSI | 25.92 | |||||
14-Day RSI | 30.06 | |||||
6-1 Month Momentum % | 15.25 | |||||
12-1 Month Momentum % | 17.66 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.69 | |||||
Quick Ratio | 4.94 | |||||
Cash Ratio | 3.17 | |||||
Days Inventory | 501.6 | |||||
Days Sales Outstanding | 149.26 | |||||
Days Payable | 115.75 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.8 | |||||
Shareholder Yield % | 2.17 |
Profitability Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 86.16 | |||||
Operating Margin % | 32.27 | |||||
Net Margin % | 30.14 | |||||
FCF Margin % | 27.96 | |||||
ROE % | 16.33 | |||||
ROA % | 12.74 | |||||
ROIC % | 21.07 | |||||
ROC (Joel Greenblatt) % | 46.93 | |||||
ROCE % | 15.39 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 25.94 | |||||
Forward PE Ratio | 20.08 | |||||
PE Ratio without NRI | 22.47 | |||||
Shiller PE Ratio | 32.9 | |||||
Price-to-Owner-Earnings | 37.29 | |||||
PEG Ratio | 1.27 | |||||
PS Ratio | 7.82 | |||||
PB Ratio | 3.8 | |||||
Price-to-Tangible-Book | 3.96 | |||||
Price-to-Free-Cash-Flow | 27.96 | |||||
Price-to-Operating-Cash-Flow | 22.32 | |||||
EV-to-EBIT | 21.25 | |||||
EV-to-Forward-EBIT | 17.28 | |||||
EV-to-EBITDA | 19.35 | |||||
EV-to-Forward-EBITDA | 16.35 | |||||
EV-to-Revenue | 6.92 | |||||
EV-to-Forward-Revenue | 6.55 | |||||
EV-to-FCF | 24.76 | |||||
Price-to-Projected-FCF | 1.51 | |||||
Price-to-DCF (Earnings Based) | 0.72 | |||||
Price-to-DCF (FCF Based) | 0.89 | |||||
Price-to-Median-PS-Value | 0.98 | |||||
Price-to-Peter-Lynch-Fair-Value | 1 | |||||
Price-to-Graham-Number | 1.99 | |||||
Price-to-Net-Current-Asset-Value | 7.97 | |||||
Price-to-Net-Cash | 26.39 | |||||
Earnings Yield (Greenblatt) % | 4.71 | |||||
FCF Yield % | 3.71 | |||||
Forward Rate of Return (Yacktman) % | 23.39 |